Category: Pharma News
-
AHA 2025: Amgen’s Repatha cuts first heart event risk by 25%
Landmark trial shows Repatha significantly reduces major cardiovascular events in high-risk patients without prior heart attack or stroke.
-
Molecular Partners unveils first human data for cancer radiotherapy
The company reveals first human data for its DLL3-targeting radiopharmaceutical MP0712, showing precise tumor targeting and limited healthy organ exposure.
-
Chiesi licenses AbbVie unit’s brain-targeting tech for rare diseases
The partnership with Aliada Therapeutics centers on a platform technology designed to ferry large-molecule therapies across the protective blood-brain barrier (BBB) for lysosomal storage disorders (LSDs).
-
Nektar’s Treg therapy shows promise in dermatitis and asthma
Treg-targeting biologic, rezpegaldesleukin (Rezpeg), demonstrates significant improvement in asthma control for patients with atopic dermatitis.
-
Teva unveils real-world findings for tardive dyskinesia treatment
Teva’s latest study finds Austedo and Austedo XR reduce involuntary movements and improve quality of life in tardive dyskinesia patients.
-
AAVantgarde closes $141 million Series B for genetic disease therapies
The company plans to use the Series B funding to progress clinical trials for two genetic eye disorders, Stargardt disease and Usher 1B syndrome.
-
BOOST Pharma raises $3.5 million for rare disease stem cell therapy
The Danish company plans to use the funds to advance its stem cell therapy, BT-101, for osteogenesis imperfecta, also known as brittle bone disease.
-
Intensity bolsters survival data for its intratumoral cancer therapy
The company’s stock shot up by approximately 394%, driven by the cancer therapy’s strong overall survival and disease control results.
-
Kymera unveils preclinical data for oral autoimmune therapy
The Massachusetts-based company’s oral therapy KT-579 shows promise in preclinical models for lupus, rheumatoid arthritis, and Sjögren’s syndrome.
-
ten23 health and Neumirna partner to advance RNA therapy for epilepsy
The collaboration seeks to advance NMT.001, an RNA-based therapy targeting microRNAs involved in drug-resistant epilepsy.
-
Affibody’s psoriatic arthritis therapy shows long-term promise
New 52-week data for izokibep in psoriatic arthritis show sustained efficacy and a favorable safety profile.
-
Bayer scores UK NICE nod for Nubeqa in prostate cancer
NICE approves Bayer’s Nubeqa (darolutamide) plus androgen deprivation therapy (ADT) for treating men with hormone-sensitive metastatic prostate cancer.
Latest posts
-
Navigating the Risks and Rewards of Biomarker-Based Surrogates and Accelerated Approval
The risks and rewards of biomarker-based surrogates are crucial for optimizing clinical trial outcomes and guiding effective treatments.
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Promis reports first human evidence of aβ oligomer reduction by pmn310
PMN310 demonstrates dose-dependent reduction of amyloid-beta oligomers in human CSF, marking a key milestone in Alzheimer’s treatment development.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.